SCHEMBL20119919

SCHEMBL20119919

Clc1nc(NCc2cccnc2)c2cc[nH]c2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.50
RAD52 P43351 1/20 0.50
ALDH1A1 P00352 4/20 0.49
CYP1A2 P05177 4/20 0.49
CYP3A4 P08684 4/20 0.49
CYP2D6 P10635 4/20 0.49
CYP2C19 P33261 4/20 0.49
TSHR P16473 3/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
MAPK1 P28482 2/20 0.49
CLK4 Q9HAZ1 2/20 0.49
USP2 O75604 1/20 0.49
PDE5A O76074 4/20 0.48
POLB P06746 1/20 0.48
CYP2C9 P11712 1/20 0.48
HSD17B10 Q99714 2/20 0.47
KDM4C Q9H3R0 1/20 0.47
APP P05067 1/20 0.47
MAPT P10636 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119397 0.84 PDE5A (0.48) PDE5APOLBAPPPDE10A
SCHEMBL29833956 0.84 PDE5A (0.48) PDE5APOLBAPPPDE10A
SCHEMBL20119986 0.83 APP (0.42) PKMRAD52ALDH1A1CYP1A2CYP3A4
SCHEMBL20119612 0.80 EGFR (0.38) ALDH1A1CYP1A2CYP3A4MEN1KMT2A
SCHEMBL20119599 0.80 PDE2A (0.41) CLK4PDE5AAPP
SCHEMBL20119845 0.79 APP (0.44) ALDH1A1CLK4PDE5AAPPKDM4E
SCHEMBL3852234 0.79 KDM4C (0.49) PKMRAD52ALDH1A1CYP1A2CYP3A4
SCHEMBL20119765 0.78 TGFBR1 (0.40) CLK4PDE5AAPP
SCHEMBL20119407 0.78 KCNH3 (0.43) CYP1A2CYP3A4CLK4
SCHEMBL20119420 0.77 PDE5A (0.38) ALDH1A1TSHRCLK4PDE5AAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 PKM 2258/4885RAD52 3364/4885ALDH1A1 2393/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 PKM 2258/4885RAD52 3364/4885ALDH1A1 2393/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 PKM 2258/4885RAD52 3364/4885ALDH1A1 2393/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 PKM 2258/4885RAD52 3364/4885ALDH1A1 2393/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 PKM 2258/4885RAD52 3364/4885ALDH1A1 2393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.